Commercialization
-
A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant
Newcomers looking for a way into the obesity space are developing unique methods to snag market share.
By Amy Baxter • Aug. 27, 2025 -
The biggest Big Pharma losers in the first half of 2025
What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.
By Michael Gibney • Aug. 21, 2025 -
MAHA leaders may take aim at pharma DTC advertising
RFK Jr. has his sights set on increasing advertising enforcement against pharmas, but may not come down as hard on the industry as previously thought.
By Amy Baxter • Aug. 20, 2025 -
Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market
Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole.
By Amy Baxter • Aug. 18, 2025 -
3 ways the GLP-1 market has changed shape this year
Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.
By Amy Baxter • Aug. 12, 2025 -
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
By Meagan Parrish • Aug. 8, 2025 -
Roche pushes ahead with late-comer strategy in obesity
The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.
By Amy Baxter • July 30, 2025 -
Novartis’ Zolgensma sales fall again as gene therapy market woes persist
Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?
By Michael Gibney • July 22, 2025 -
3 major patent losses this year — and a key strategy to fill the gaps
Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.
By Kelly Bilodeau • July 21, 2025 -
Q&A
Need a DTC platform? Here’s how one company built its own.
Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med.
By Amy Baxter • July 14, 2025 -
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.
By Jonathan Gardner • July 11, 2025 -
Trump says ‘very high’ pharmaceutical tariffs coming soon
While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.
By Philip Neuffer • July 9, 2025 -
GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down
As more drugmakers aim for the lucrative weight loss market, patient challenges linger.
By Amy Baxter • July 7, 2025 -
3 of the year’s most notable FDA nods
The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.
By Meagan Parrish • June 27, 2025 -
Biogen scores Cannes Festival win with dark humored campaign
The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.
By Alexandra Pecci • June 24, 2025 -
Megablockbusters are the holy grail. Here’s how drugmakers are getting there.
More drugs surpassed $10 billion in revenue last year than ever before.
By Amy Baxter • June 23, 2025 -
Is DTC pharma advertising coming to an end?
A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.
By Amy Baxter • June 18, 2025 -
The MAHA agenda won’t include expanding GLP-1 coverage — for now
Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.
By Amy Baxter • June 2, 2025 -
AbbVie’s ADC win shows how pharma can break through in solid tumors
An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.
By Meagan Parrish • May 30, 2025 -
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.
By Michael Gibney • May 8, 2025 -
With TV ads under threat, here’s how pharma can leverage social media
RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.
By Amy Baxter • May 7, 2025 -
With compounders out of the way, Lilly and Novo go after each other
The two obesity leaders are pulling on all levers to stay on top of the market.
By Amy Baxter • May 5, 2025 -
Can anything threaten Novo and Lilly’s obesity market dominance?
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.
By Amy Baxter • April 21, 2025 -
Novartis scores NFL deal to tackle health outcomes
The non-traditional marketing approach comes amid a potential crackdown on TV drug ads.
By Amy Baxter • April 17, 2025 -
Profile
The industry heavyweight behind Novavax’s push to bounce back
As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.
By Alexandra Pecci • March 25, 2025